ORLANDO, FLA. (May 19, 2002, 12:00 p.m., EST) An experimental pill has been found to improve symptoms and quality of life in patients with non-small-cell lung cancer, according to research findings presented by Ronald B. Natale, M.D., Acting Medical Director at Cedars-Sinai Comprehensive Cancer Center, and lead author of the study. The pill, called ZD 1839 (Iressa) is one of a new class of drugs that targets and blocks a key growth signal in cancer cells.
The study, presented at the 38th annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, evaluated 216 patients with recurrent non-small-cell lung cancer who had undergone two or more rounds of chemotherapy. One group of patients received 250 mg of ZD 1839 (Iressa) daily, while the second group received ZD 1839 at 500 mg each day until the disease progressed. The investigators found that lung cancer symptoms, such as cough, shortness of breath, chest pain or tightness, appetite and fatigue, were greatly improved in about 40 percent of patients. Further, they found that symptom improvement was associated with a longer survival.
Our results show that patients who felt better after taking ZD 1839, actually lived longer than those whose symptoms did not improve, said Dr. Natale. This is important because it shows that a daily pill reduced symptoms such to the extent that many of our patients were able to resume their normal activities and enjoy life for longer.
ZD 1839 (Iressa), a pill developed by AstraZeneca, has been found to work in both laboratory and clinical trials by targeting and blocking a key growth signaling mechanism in cancer cells called the epidermal growth factor receptor (EGFR). Otherwise known as HER1, the EGFR is a part of the HER kinase family of proteins that control cell growth and can stimulate the spread of cancer when over-expressed on malignant cells.
Non-small-cell lung cancer is the most common type of lung cancer,Page: 1 2 3 Related medicine news :1
Contact: Kelli Stauning
Cedars-Sinai Medical Center
. St. Jude scientist wins International Society of Experimental Hematology award2
. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows3
. Experimental drug used to treat recurrent ovarian cancer shows promising results4
. Experimental treatment yields new hope for children battling cerebral palsy5
. Experimental drugs show promise in halting brain tumors6
. Experimental drugs reduce neuron death in rats following insulin shock7
. Experimental drug reverses effects of Fabry disease in mice8
. Experimental peptides prevent diabetes and halt its progression9
. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women10
. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation11
. Acupuncture found to lower elevations in blood pressure